Navigation Links
Simcere Announces Strategic Partnership with Sun Yat-Sen University Cancer Center
Date:8/24/2009

NANJING, China, Aug. 24 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today announced a strategic partnership with Sun Yat-Sen University Cancer Center.

Located in Guangzhou, Sun Yat-Sen University Cancer Center is one of China's renowned cancer research institutions, prominent in pre-clinical and clinical oncology research. The Sun Yat-Sen University Cancer Center was established to research anti-cancer treatments with a specific focus on developing major innovative drugs.

Through the strategic partnership, Simcere Pharmaceutical Group and Sun Yat-Sen University Cancer Center will cooperate on researching and developing innovative anti-cancer drugs, as well as conducting a joint training program to develop personnel in advanced R&D.

"We are delighted to enter into a strategic partnership with Sun Yat-Sen University Cancer Center, one of China's outstanding cancer research institutions," said Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "I am confident that this cooperation will enhance Simcere's R&D capabilities and contribute to the future development of innovative cancer drugs in China."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells anti-infective medication, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2009 Results and Announces Share Repurchase
2. Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009
3. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
4. Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir
5. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
6. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
7. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
8. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
9. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
10. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
11. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important milestones. To ... $835 million in resolved debt for its clients. , Credit card debt, unpaid hospital ... of debt settled by the company. With more than a decade of combined service ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... winners of the Entrepreneur Innovation Awards (EIA), held this past Thursday night at ... Connecticut-based companies and entrepreneurs, presented their innovative project ideas to a panel of ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... of Professional Benefit Administrators (SPBA) hosted “Expanding Your Success” with an educational ... as it focused on best practices for third party administrators (TPAs) related to ...
(Date:9/19/2017)... ... ... The Semper Fi Fund, one of the nation’s highest-rated veteran nonprofits serving ... and a compelling documentary that provide unique insights and powerful advice to help address ... ongoing mission. , Each of the videos focuses on a specific issue that’s highly ...
(Date:9/19/2017)... Toronto, Ontario (PRWEB) , ... September 19, 2017 , ... ... governmental regulation of pollutants have fallen on deaf ears, leaving the water industry itself ... one company that stays ahead of the curve in the field of natural ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly and ... actions to streamline operations to more efficiently focus ... its cost structure. Global workforce reductions, including those ... expected to impact approximately 3,500 positions. ... expects annualized savings of approximately $500 million that ...
Breaking Medicine Technology: